

Ari Green

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2048020/publications.pdf>

Version: 2024-02-01

84
papers

6,638
citations

126901

33
h-index

76898

74
g-index

90
all docs

90
docs citations

90
times ranked

8017
citing authors

#	ARTICLE	IF	CITATIONS
1	Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. <i>Nature Medicine</i> , 2014, 20, 954-960.	30.7	451
2	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOMentum): a double-blind, randomised placebo-controlled phase 2/3 trial. <i>Lancet</i> , The, 2019, 394, 1352-1363.	13.7	433
3	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. <i>Lancet Neurology</i> , The, 2017, 16, 797-812.	10.2	397
4	Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. <i>Brain</i> , 2010, 133, 1591-1601.	7.6	392
5	Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. <i>Lancet</i> , The, 2017, 390, 2481-2489.	13.7	377
6	Systematic integration of biomedical knowledge prioritizes drugs for repurposing. <i>ELife</i> , 2017, 6, .	6.0	333
7	The APOSTEL recommendations for reporting quantitative optical coherence tomography studies. <i>Neurology</i> , 2016, 86, 2303-2309.	1.1	331
8	Long-term evolution of multiple sclerosis disability in the treatment era. <i>Annals of Neurology</i> , 2016, 80, 499-510.	5.3	331
9	Microcystic macular oedema in multiple sclerosis is associated with disease severity. <i>Brain</i> , 2012, 135, 1786-1793.	7.6	300
10	Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. <i>Lancet Neurology</i> , The, 2012, 11, 963-972.	10.2	267
11	Silent progression in disease activity-free relapsing multiple sclerosis. <i>Annals of Neurology</i> , 2019, 85, 653-666.	5.3	265
12	Accelerated remyelination during inflammatory demyelination prevents axonal loss and improves functional recovery. <i>ELife</i> , 2016, 5, .	6.0	210
13	Blood GFAP as an emerging biomarker in brain and spinal cord disorders. <i>Nature Reviews Neurology</i> , 2022, 18, 158-172.	10.1	205
14	Rituximab before and during pregnancy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e453.	6.0	159
15	The Spectrum of Neurologic Disease in the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic Infection. <i>JAMA Neurology</i> , 2020, 77, 679.	9.0	152
16	Infliximab for the treatment of CNS sarcoidosis. <i>Neurology</i> , 2017, 89, 2092-2100.	1.1	151
17	Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	147
18	Transcriptional profiling and therapeutic targeting of oxidative stress in neuroinflammation. <i>Nature Immunology</i> , 2020, 21, 513-524.	14.5	118

#	ARTICLE	IF	CITATIONS
19	Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study. <i>Journal of Neurology</i> , 2016, 263, 1323-1331.	3.6	112
20	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. <i>Neurology</i> , 2021, 97, 68-79.	1.1	96
21	Early retinal neurodegeneration and impaired Ran-mediated nuclear import of TDP-43 in progranulin-deficient FTLD. <i>Journal of Experimental Medicine</i> , 2014, 211, 1937-1945.	8.5	94
22	Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination. <i>Journal of Neuroscience</i> , 2016, 36, 7925-7935.	3.6	90
23	Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 897.	9.0	78
24	Oligodendrocyte-encoded Kir4.1 function is required for axonal integrity. <i>ELife</i> , 2018, 7, .	6.0	71
25	Association of Continuous Assessment of Step Count by Remote Monitoring With Disability Progression Among Adults With Multiple Sclerosis. <i>JAMA Network Open</i> , 2019, 2, e190570.	5.9	69
26	Tolerance checkpoint bypass permits emergence of pathogenic T cells to neuromyelitis optica autoantigen aquaporin-4. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 14781-14786.	7.1	59
27	Reduced contrast sensitivity among older women is associated with increased risk of cognitive impairment. <i>Annals of Neurology</i> , 2018, 83, 730-738.	5.3	52
28	Toward a low-cost, in-home, telemedicine-enabled assessment of disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1526-1534.	3.0	49
29	Selective Estrogen Receptor Modulators Enhance CNS Remyelination Independent of Estrogen Receptors. <i>Journal of Neuroscience</i> , 2019, 39, 2184-2194.	3.6	49
30	Prion Seeds Distribute throughout the Eyes of Sporadic Creutzfeldt-Jakob Disease Patients. <i>MBio</i> , 2018, 9, .	4.1	48
31	Remyelinating Pharmacotherapies in Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 894-904.	4.4	46
32	Retinal thinning is uniquely associated with medial temporal lobe atrophy in neurologically normal older adults. <i>Neurobiology of Aging</i> , 2017, 51, 141-147.	3.1	44
33	Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. <i>Annals of Neurology</i> , 2022, 91, 268-281.	5.3	39
34	Optical coherence tomography in multiple sclerosis: A 3-year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2235-2251.	3.7	36
35	Clinic to in-home telemedicine reduces barriers to care for patients with MS or other neuroimmunologic conditions. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e505.	6.0	35
36	A randomized controlled phase II trial of riluzole in early multiple sclerosis. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 340-347.	3.7	33

#	ARTICLE	IF	CITATIONS
37	Artificial intelligence extension of the OSCAR criteria. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1528-1542.	3.7	33
38	Early complement genes are associated with visual system degeneration in multiple sclerosis. <i>Brain</i> , 2019, 142, 2722-2736.	7.6	30
39	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. <i>Brain</i> , 2020, 143, 1127-1142.	7.6	29
40	Neurologic Complications of Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2016, 36, 793-800.	3.8	28
41	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. <i>Journal of Neuroinflammation</i> , 2019, 16, 203.	7.2	28
42	Magnetic resonance imaging correlates of clinical outcomes in early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 720-727.	2.0	26
43	Encephalitis of Unclear Origin Diagnosed by Brain Biopsy. <i>JAMA Neurology</i> , 2015, 72, 66.	9.0	26
44	Harnessing electronic medical records to advance research on multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 408-418.	3.0	21
45	Sex differences and subclinical retinal injury in pediatric-onset MS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 447-455.	3.0	19
46	Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy. <i>Brain</i> , 2022, 145, 3943-3952.	7.6	19
47	Relation of quantitative visual and neurologic outcomes to fatigue in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2015, 4, 304-310.	2.0	18
48	pRNFL as a marker of disability worsening in the medium/long term in patients with MS. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, e533.	6.0	18
49	Fixational microsaccades: A quantitative and objective measure of disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 343-353.	3.0	16
50	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 57, 103356.	2.0	16
51	Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. <i>American Journal of Neuroradiology</i> , 2020, 41, 2219-2226.	2.4	14
52	Retinal INL Thickness in Multiple Sclerosis: A Mere Marker of Neurodegeneration?. <i>Annals of Neurology</i> , 2021, 89, 192-193.	5.3	14
53	Distinctive waves of innate immune response in the retina in experimental autoimmune encephalomyelitis. <i>JCI Insight</i> , 2021, 6, .	5.0	14
54	Using Optical Coherence Tomography and Optokinetic Response As Structural and Functional Visual System Readouts in Mice and Rats. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	13

#	ARTICLE	IF	CITATIONS
55	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 188-195.	1.9	13
56	Retinal architecture and mfERG. <i>Neurology</i> , 2014, 82, 1888-1896.	1.1	12
57	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2052-2061.	3.0	11
58	Whole-body positional manipulators for ocular imaging of anaesthetised mice and rats: a do-it-yourself guide. <i>BMJ Open Ophthalmology</i> , 2016, 1, e000008.	1.6	9
59	Suprasellar Germinoma and Late Perioptic Seeding. <i>European Journal of Ophthalmology</i> , 2008, 18, 159-161.	1.3	7
60	Subclinical Saccadic Eye Movement Dysfunction in Pediatric Multiple Sclerosis. <i>Journal of Child Neurology</i> , 2019, 34, 38-43.	1.4	7
61	Transitioning From S1P Receptor Modulators to B Cell “Depleting Therapies in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	7
62	Plasma neurofilament light chain levels suggest neuroaxonal stability following therapeutic remyelination in people with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 972-977.	1.9	7
63	Color perception impairment following optic neuritis and its association with retinal atrophy. <i>Journal of Neurology</i> , 2019, 266, 1160-1166.	3.6	6
64	T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury. <i>Journal of Nature and Science</i> , 2017, 3, .	1.1	6
65	Combating the Spread of Ineffective Medical Procedures. <i>JAMA Neurology</i> , 2018, 75, 15.	9.0	5
66	Imaging correlates of visual function in multiple sclerosis. <i>PLoS ONE</i> , 2020, 15, e0235615.	2.5	5
67	A hormonal therapy for menopausal women with MS: A phase Ib/IIa randomized controlled trial. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 61, 103747.	2.0	5
68	Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4. <i>Journal of Visualized Experiments</i> , 2017, , .	0.3	4
69	Underutilization of physical therapy for symptomatic women with MS during and following pregnancy. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102703.	2.0	4
70	Characterizing Fixational Eye Motion Variance Over Time as Recorded by the Tracking Scanning Laser Ophthalmoscope. <i>Translational Vision Science and Technology</i> , 2022, 11, 35.	2.2	3
71	Reply to “Interpretation of Longitudinal Changes of the Inner Nuclear Layer in MS” <i>Annals of Neurology</i> , 2022, 92, 156-156.	5.3	3
72	OCT is an alternative to MRI for monitoring MS “ Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 705-706.	3.0	2

#	ARTICLE	IF	CITATIONS
73	Potential Benefits of Early Aggressive Treatment in Multiple Sclerosis. JAMA Neurology, 2019, 76, 254.	9.0	1
74	Lessons from an unsuccessful therapeutic trial. Lancet Neurology, The, 2019, 18, 808-810.	10.2	0
75	Personalizing medical care for patients with MS. Neurology, 2019, 92, 929-930.	1.1	0
76	Importance of Not MSing Cerebral White Matter Disease in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2020, 65, 2527-2532.	2.3	0
77	MRI findings in blinded trials should be available to treating physicians â€“ Commentary. Multiple Sclerosis Journal, 2021, 27, 816-817.	3.0	0
78	Vitamin B12 is inversely correlated with latency of multifocal visual evoked potential in healthy older adults. FASEB Journal, 2011, 25, 97.2.	0.5	0
79	Reply to â€œSpinal Cord Atrophy Is a Preclinical Marker of Progressive <sc>MS</sc>â€“. Annals of Neurology, 2022, 91, 735-736.	5.3	0
80	Socioeconomic disadvantage in multiple sclerosis: does inequality act on the substrate for disability?. Brain, 2021, 144, 3552-3554.	7.6	0
81	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
82	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
83	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0
84	Imaging correlates of visual function in multiple sclerosis. , 2020, 15, e0235615.		0